Table 1Excluded studies at the full text level from primary search

Excluded because citation was not a full text systematic review, study or trial (n=66)
Ahmad K, McDonnell TJ, Rogers S. Does prior treatment with fumaric acid esters predispose to tuberculosis in patients on etanercept? Clin Exp Dermatol 2007;32:329.
Amital H, Ingber A, Rubinow A. Infliximab-induced remission of extensive plaque psoriasis. Isr med Assoc J 2003;5:827–28.
Balato N, Gallo L, Gaudiello F, et al. Transient and reversible thrombocytopenia in a psoriatic patient treated with etanercept. J Dermatolog Treat 2010;21:117–18.
Bansal C, Leonardi C, Van Voorhees AS. Persistent CD4+ T cell depression following combination alefacept and methotrexate therapy. Int J Dermatol 2008;47:1204–06.
Barland C, Kerdel FA. Addition of low-dose methotrexate to infliximab in the treatment of a patient with severe, recalcitrant pustular psoriasis. Arch Dermatol 2003;139:949–50.
Belinchon J, Lucas A, Mataix J, Perez-Crespo M, Silvestre J, Betlloch I. Therapy-resistant psoriasis treated with adalimumab and concomitant narrow band ultraviolet B phototherapy with clearing of psoriasis. J Eur Acad Dermatol Venereol 2007;21:22.
Berns MW, McCullough JL. Porphyrin sensitized phototherapy. Arch Dermatol 1986;122:871–74.
Boulinguez S. [News on psoriasis from the 2010 Dermatology Days in Paris] Ann Dermatol Venereol 2011;138(Suppl 1):H1.
Carrascosa J M, Soria X, Ferrandiz C. Effective management of a psoriatic flare with narrowband UVB phototherapy during efalizumab therapy without discontinuing treatment. J Eur Acad Dermatol Venereol 2007;21:828–29.
Dalaker M, Bonesronning JH. [Treatment of severe psoriasis with anti-TNF-alpha-antibody and methotrexate]. Tidsskr Nor Laegeforen 2003;123:1070–71.
Daulat S, Detweiler JG, Pandya AG. Development of pemphigus vulgaris in a patient with psoriasis treated with etanercept. J Eur Acad Dermatol Venereol 2009;23:483–84.
Davison SC, Bunker CB, Basarab T. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br J Dermatol 2002;147:831–32.
Dawe RS. Using ‘number needed to treat’ to express the magnitudes of benefit of ultraviolet B phototherapy and of antitumour necrosis factor-alpha therapies for psoriasis. Br J Dermatol 2010;162:456–57.
Drijkoningen M, De Wolf-Peeters C, Roelandts R, et al. A morphological and immunohistochemical study of phytophotodermatitis-like bullae induced by PUVA. Photodermatol 1986;3:199–201.
Dubin DB, Tanner W, Ellis R. Biologics for psoriasis. Nat Rev Drug Discov 2003;2:855–56.
Egnatios G, Warthan MM, Pariser R, et al. Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors. J Drugs Dermatol 2008;7:975–77.
Elewski BE. Infliximab for the treatment of severe pustular psoriasis. J Am Acad Dermatol 2002;47:796–97.
Fiala K, Schierl M, Breier F, et al. Transient paresis of the right recurrent laryngeal nerve after treatment with etanercept for plaque-type psoriasis. Eur J Dermatol 2010;20:818–19.
Gonzalo-Garijo MA, Perez-Calderon R, de Argila Fernandez-Duran D. Severe generalized exanthema due to etanercept given for severe plaque psoriasis. Ann Allergy Asthma Immunol 2008;100:621–22.
Gonzalo-Garijo M A, Rodriguez-Nevado I, Perez-Calderon R, et al. Severe cutaneous reaction and fever due to adalimumab. Ann Allergy Asthma Immunol 2010;105:490–91.
Heikkila H, Ranki A, Cajanus S, et al. Infliximab combined with methotrexate as long-term treatment for erythrodermic psoriasis. Arch Dermatol 2005;141:1607–10.
Honigsmann H. Comparison of psoralen plus ultraviolet A therapy and biologics in moderate to severe chronic plaque psoriasis. Br J Dermatol 2011;165:455–56.
Jackle R. [Vitamin D3 analogs, oral fumaric acid, TNF-alpha antibodies. New hope for patients with psoriasis]. MMW Fortschr Med 2001;143:4–8.
Jaiswal R, Darabi K, Bechtel M, Zirwas M, Hostetler S. Spontaneous epidural abscess and subsequent quadriplegia in a psoriasis patient treated with etanercept and methotrexate. J Am Acad Dermatol 2009;60:AB170.
Katz KA. Psoriasis Area and Severity Index 50 as an endpoint in psoriasis trials: an unconvincing proposal. J Am Acad Dermatol 2005;53:547–51.
Kerner M, Rozenman D, Ziv M. Combination therapy with cyclosporine A and an anti-TNF alpha agent (adalimumab) in the treatment of severe psoriasis. J Am Acad Dermatol 2011;64:AB161.
Kincaid L. Psoriasis: TNF-alpha inhibitors and beyond. Drug Discov Today 2005;10:884–86.
Kluger N, Girard C, Guillot B, et al. Efficiency and safety of etanercept after acute hepatitis induced by infliximab for psoriasis. Acta Derm Venereol 2009;89:332–34.
Lee MR, Cooper AJ. Use of infliximab in the treatment of psoriasis. Australas J Dermatol 2004;45:193–95.
Leonardi C. Rebound in patients abruptly discontinued from etanercept. J Am Acad Dermatol 2005;52:P193.
Lima HC, Kubo E, Rosas F, Santamaria JR, Moraes L. Combining biologics and cyclosporine for psoriasis treatment. J Am Acad Dermatol 2009;60:AB179.
Lucas A, Belinchon I, Perez-Crespo M, et al. Successful response to narrow-band UVB in a patient undergoing concomitant treatment with adalimumab for psoriasis. Australas J Dermatol 2008;49:173–74.
McCluggage LK, Hussar DA. New drugs: Ustekinumab, tocilizumab, and telavancin hydrochloride. J Am Pharm Assoc 2010;50:324–27.
Menter A. Goeckerman therapy versus biologics in the treatment of psoriasis. J Am Acad Dermatol 2010;62:516–17.
Mocciaro F, Renna S, Orlando A, et al. Severe cutaneous psoriasis after certolizumab pegol treatment: report of a case. Am J Gastroenterol 2009;104:2867–68.
Mrowietz U, Barth J, Boehncke WH, et al. [Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept]. J Deutschen Dermatologischen Gesellschaft 2005;3:470–72.
Naidoo P, Rambiritch V. Voclosporin (ISA247) for plaque psoriasis. Lancet 2008;372:888–89.
Nakagomi D, Harada K, Yagasaki A, et al. Psoriasiform eruption associated with alopecia areata during infliximab therapy. Clin Exp Dermatol 2009;34:923–24.
Naldi L. The search for effective and safe disease control in psoriasis. Lancet2008;371:1311–12.
Nallamothu PG, Nallamothu BK, Lim HW. Etanercept in patients with moderate to severe psoriasis who fail methotrexate: a cost-effectiveness analysis. J Invest Dermatol 2004;122:378.
Nijsten T, Spuls PI. Adalimumab may be better or no worse than methotrexate in the treatment of psoriasis. Br J Dermatol 2008;159:257–58.
Nikkels AF, Pierard GE. Etanercept and recalcitrant acrodermatitis continua of Hallopeau. J Drugs Dermatol 2006;5:705–06.
Olivieri I, D’Angelo S, Leccese P, et al. Worsening of psoriasis with rituximab therapy. Clin Exp Rheumatol 2010;28:926.
Ozdemir M, Mevlitoglu I, Balevi A. Acitretin narrow-band TL-01 phototherapy but not etanercept treatment improves a localized inflammatory linear verrucous epidermal naevus with concomitant psoriasis. J Eur Acad Dermatol Venereol 2009;23:1453–54.
Papadavid E, Makris M, Dalamaga M, et al. Recall injection-site reactions to etanercept in a patient with psoriasis. Clin Exp Dermatol 2009;34:414–15.
Pereira TM, Vieira AP, Fernandes JC, et al. Anti-TNF-alpha therapy in childhood pustular psoriasis. Dermatology 2006;213:350–52.
Rallis E, Verros CD. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies. Dermatol Online J 2011;17:14.
Rallis E, Verros CD. Ustekinumab treats psoriasis refractory to seven conventional and biologic therapies. Dermatol Online J 2011;17:14.
Renner R, Colsman A, Sticherling M. ILVEN: is it psoriasis? Debate based on successful treatment with etanercept. Acta Derm Venereol 2008;88:631–32.
Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. J Am Acad Dermatol 2006;54:361–62.
Strober BE. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab. J Am Acad Dermatol 2004;50:P570.
Strober BE. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab. Arch Dermatol 2004;140:366.
Tan E, Grattan C. Non-Hodgkin’s T-cell lymphoma in a patient with erythrodermic pustular psoriasis treated with infliximab, cyclosporine, and methotrexate. J Am Acad Dermatol 2006;54:AB204.
Taniguchi Y, Kumon Y, Shimamura Y, et al. Rapidly progressive destructive arthritis in psoriatic arthritis sine psoriasis: do bone resorption marker levels predict outcome of bone destruction in psoriatic arthritis? Mod Rheumatol 2011;21:106–108.
Thielen AM, Barde C, Saurat JH. Infliximab- and methotrexate-resistant rebound of psoriasis after discontinuation of efalizumab (Raptiva). Br J Dermatol 2006;155:846–47.
Toledo Alberola F, Ballester Nortes I, Belinchon Romero I, Betlloch Mas I, Cuesta Montero L. Concomitant treatment with adalimumab and narrowband UVB for severe plaque psoriasis: Report of three cases. J Am Acad Dermatol 2011;64 2:AB162.
Tun TT, Dewitt CA, Stone SP. The combination of alefacept and acitretin for the treatment of chronic plaque psoriasis. J Am Acad Dermatol 2006;54:AB225.
Tuxen AJ, Yong MK, Street AC, et al. Disseminated cryptococcal infection in a patient with severe psoriasis treated with efalizumab, methotrexate and ciclosporin. Br J Dermatol 2007;157:1067–68.
Ventura F, Gomes J, Duarte Mda L, et al. Efficacy and safety of etanercept in patients with psoriasis and hepatitis C. Eur J Dermatol 2010;20:808–09.
Warren RB, Brown BC, Carmichael AJ, et al. Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 2009;34:415–16.
Yamauchi P, Lowe N. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis. J Am Acad Dermatol 2005;52:P1.
Yamauchi PS, Lowe NJ. Cessation of cyclosporine therapy by treatment with etanercept in patients with severe psoriasis. J Am Acad Dermatol 2006;54:S135–38.
Yamauchi P, Lowe N, Koo S. Etanercept therapy allows tapering of methotrexate and sustained clinical responses in patients with moderate to severe psoriasis. J Am Acad Dermatol 2005;52:P185.
Yamauchi PS, Lowe NJ, Gindi V. Treatment of coexisting bullous pemphigoid and psoriasis with the tumor necrosis factor antagonist etanercept. J Am Acad Dermatol 2006;54:S121–22.
Yang YS, Haw CR, Lee EJ, Cho HR, Kim NI. Severe psoriasis in identical twin treated with etanercept and low-dose cyclosporine. J Am Acad Dermatol 2009;60:AB178.
No authors listed. [Aldalimumab in psoriatic arthritis and as the initial therapy in rheumatoid arthritis]. Krankenpfl J 2005;43:244.
Excluded because the population was not human adults (n=2)
Moore A, Wright E, Ostrowski L, Moore T. Etanercept and narrowband UVB combination therapy for plaque-type psoriasis shortens onset of action in both adults and children. J Am Acad Dermatol 2006;54:AB217.
Sasson M, Stiller MJ, Shupack JL, et al. Antibody titers to an oxidized thymidine moiety are altered by systemic pharmacotherapy and by ultraviolet B phototherapy. Arch Dermatol Res 1993;285:227–29.
Excluded because the population was not patients with chronic plaque psoriasis or psoriasis vulgaris (n=14)
Bose F, Raeli L, Garutti C, et al. Dual role of anti-TNF therapy: enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of inflammation in target tissues. Clin Immunol 2011;139:164–76.
Cassano N, Loconsole F, Amoruso A, et al. Infliximab monotherapy for refractory psoriasis: preliminary results. Int J Immunopathol Pharmacol 2004;17:373–80.
Dai WW, Moore AY. Combination regimen of acitretin and adalimumab for moderate to severe psoriasis. J Am Acad Dermatol 2010;62:AB132.
Kamili QU, Miner A, Hapa A, et al. Infliximab treatment for psoriasis in 120 patients on therapy for a minimum of one year: a review. J Drugs Dermatol 2011;10:539–44.
Mease PJ. Cytokine blockers in psoriatic arthritis. Ann Rheum Dis 2001;60:37–40.
Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004;50:2264–72.
Moore A, Wright E, Slay D, Castillo A. Alefacept and low-dose acitretin therapy for inverse psoriasis and palmar/plantar psoriasis shortens onset of action. J Am Acad Dermatol 2006;54:AB211.
Ogilvie AL, Antoni C, Dechant C, et al. Treatment of psoriatic arthritis with antitumour necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment with methotrexate. Br J Dermatol 2001;144:587–89.
Salvarani C, Cantini F, Olivieri I, et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum 2003;49:541–45.
Sánchez-Regaña M, Sola-Ortigosa J, Alsina-Gibert M, et al. Nail psoriasis: a retrospective study on the effectiveness of systemic treatments (classical and biological therapy). J Eur Acad Dermatol Venereol. 2011;25:579–86.
Saraceno R, Schipani C, Mazzotta A, et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res 2008;57:290–95.
Spuls PI, Hadi S, Rivera L, et al. Retrospective analysis of the treatment of psoriasis of the palms and soles. J Dermatolog Treat 2003;14:21–25.
Worlicek C, Kaufmann R, Thaci D. Combination Therapy of Etanercept and Acitretin in Treatment-Resistant Palmoplantar pustular Psoriasis in the Long-Term Control. J Dtsch Dermatol Ges 2011;9:221.
Excluded because the study was not controlled or a before and after study (n=8)
de Miguel R, el-Azhary R. Efficacy, safety, and cost of Goeckerman therapy compared with biologics in the treatment of moderate to severe psoriasis. Int J Dermatol 2009;48:653–58.
Kircik L, Elmets C, Menter A, Koo J. Utilization of narrow-band UVB light therapy and etanercept for the treatment of psoriasis (UNITE): Characteristics of PASI responders. J Am Acad Dermatol 2007;56:AB5.
Landells I, Searles G, Bissonnette R, et al. Efficacy outcomes in patients using alefacept in the AWARE study. J Cutan Med Surg 2009;13:S122–30.
Martin B, Sanchez-Carazo JL, Perez-Ferriols A, et al. [Clinical experience with etanercept in the treatment of psoriasis]. Actas Dermosifiliogr 2008;99:540–45.
Marzo-Ortega H, McGonagle D, Rhodes LA, et al. Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. Ann Rheum Dis 2007;66:778–81.
Moore A, Slay D, Wright E, Moore T. Alefacept and narrowband UVB combination therapy for psoriasis shortens onset of action. J Am Acad Dermatol 2006;54:AB212.
Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29–35.
van de Kerkhof P, Griffiths CE, Christophers E, et al. Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. Dermatology 2005;211:256–63.
Excluded because the study did not compare a single biologic to a single non-biologic or phototherapy (n=49)
Ahmad K, Rogers S. Two years of experience with etanercept in recalcitrant psoriasis. Br J Dermatol 2007:156:1010–14.
Ahmad K, Rogers S. Three years’ experience with infliximab in recalcitrant psoriasis. Clin Exp Dermatol 2006;31:630–33.
Antoniou C, Stefanaki I, Stratigos A, et al. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre. Br J Dermatol 2010;162:1117–23.
Ardigo M, Giuliani A, de Felice C, et al. Efficacy of adalimumab in plaque psoriasis: experience on 28 patients. J Drugs Dermatol 2008;7:935–39.
Boehncke S, Salgo R, Garbaraviciene J, et al. Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. J Eur Acad Dermatol Venereol 2011;25:1187–93.
Caldarola G, De Simone C, Carbone A, et al. TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept. Int J Immunopathol Pharmacol 2009;22:961–66.
Campanati A, Goteri G, Simonetti O, et al. CTACK/CCL27 expression in psoriatic skin and its modification after administration of etanercept. Br J Dermatol 2007;157:1155–60.
de Groot M, Teunissen MB, Picavet DI, et al. Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment. Exp Dermatol 2010;19:754–56.
De Oliveira JP, Levy A, Morel P, et al. Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment. J Dermatol 2008;35:575–80.
Gambichler T, Kobus S, Kobus A, et al. Expression of antimicrobial peptides and proteins in etanercept-treated psoriasis patients. Regul Pept 2011;167:163–66.
Gambichler T, Kreuter A, Scola N, Tigges C, Skrygan M. Etanercept plus narrowband UVB phototherapy is superior to etanercept monotherapy of psoriasis. J Eur Acad Dermatol Venereol 2010;24:P102.
Gambichler T, Terras S, Tigges C, et al. Etanercept plus narrowband ultraviolet B phototherapy of psoriasis is more effective than etanercept mono-therapy at 6-weeks. J Invest Dermatol 2011;131:S39.
Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther 2004;6;R326–34.
Gonzalez-Chavez JR, Berlingeri-Ramos AC, Sanchez Casiano MA. Puerto Rico psoriasis study group: efficacy and safety of etanercept. J Drugs Dermatol 2005;4:735–39.
Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005;175:2721–29.
Horrocks C, Duncan JI, Sewell HF, et al. Differential effects of cyclosporine A on Langerhans cells and regulatory T-cell populations in severe psoriasis: an immunohistochemical and flow cytometric analysis. J Autoimmun 1990;3:559–70.
Ieiri I, Nakayama J, Murakami H, et al. Evaluation of the therapeutic range of whole blood cyclosporin concentration in the treatment of psoriasis. Int J Clin Pharmacol Ther 1996;34:106–11.
Jacobe H, Winterfield L. Efficacy and safety of alefacept in combination with narrowband UVB for the treatment of plaque psoriasis. J Am Acad Dermatol 2006;54:AB217.
Jones-Caballero M, Unaeze J, Penas PF, et al. Use of biological agents in patients with moderate to severe psoriasis: a cohort-based perspective. Arch Dermatol 2007;143:846–50.
Kalb RE, Gurske J. Infliximab for the treatment of psoriasis: clinical experience at the State University of New York at Buffalo. J Am Acad Dermatol 2005;53:616–22.
Kanelleas A, Liapi C, Katoulis A, et al. The role of inflammatory markers in assessing disease severity and response to treatment in patients with psoriasis treated with etanercept. Clin Exp Dermatol 2011;36:845–50.
Kokelj F, Miertusova Tothova S, Patamia M, et al. Our experience with etanercept in the treatment of psoriasis. Acta Dermatovenerol Croat 2006;14:241–45.
Koo JY, Bagel J, Sweetser MT, et al. Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study. J Drugs Dermatol 2006;5:623–28.
Krathen RA, Berthelot CN, Hsu S. Sustained efficacy and safety of infliximab in psoriasis: a retrospective study of 73 patients. J Drugs Dermatol 2006;5:251–54.
Krishnan R, Cella D, Leonardi C, et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br J Dermatol 2007;157:1275–77.
Krueger GG, Gottlieb AB, Sterry W, et al. A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. J Dermatolog Treat 2008;19:146–55.
Legat FJ, Hofer A, Wackernagel A, Salmholer W, Kerl H, Wolf P. Alefacept plus 311 nm narrowband ultraviolet B (NB-UVB) phototherapy in the treatment of psoriasis. J Invest Dermatol 2005;125:925.
Legat LJ, Hofer A, Wackernagel A, et al. Alefacept plus 311 nm narrowband ultraviolet B (NB-UVB) phototherapy in the treatment of psoriasis [abstract]. J Invest Dermatol 2005;125:A4.
Lui H, Tan J, Shear N, Bissonnette R, Gulliver W. Efficacy and safety of alefacept in combination with narrowband UVB compared to alefacept alone in subjects with moderate to severe psoriasis: Results of the Canadian alefacept phototherapy psoriasis study. J Am Acad Dermatol 2011;64:AB150.
Mazzotta A, Esposito M, Schipani C, et al. Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study. J Dermatolog Treat 2009;20:354–58.
Moore A, Wright E, Slay D, Moore T. Alefacept, acitretin, and narrowband UVB combination therapy for plaque-type psoriasis allows faster withdrawal and shortens onset of action. J Am Acad Dermatol 2006;54:AB11.
Na JI, Kim JH, Park KC, et al. Low-dose etanercept therapy in moderate to severe psoriasis in Korean. J Dermatol 2008;35:484–90.
Ortonne JP, Griffiths CEM, Dauden E, et al. Efficacy and safety of continuous versus paused etanercept teatment in patients with moderate-to-severe psoriasis over 54 weeks: The CRYSTEL Study. Expert Review of Dermatology 2008;3:657.
Panigalli S, Coccarielli D, Germi L, et al. Non-randomized pilot study on the evaluation of the quality of life and psychosocial stress before and after systemic therapy in patients affected by moderate to severe psoriasis. J Biol Regul Homeost Agents 2009;23:111–17.
Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005;152:1304–12.
Park K, Kamangar F, Heller M, Bhutani T, Lee E. A Single-Center, Open-Label, Pilot Study to Evaluate the Efficacy and Tolerability of Narrow Band UVB Phototherapy in Enhancing Etanercept’s Maintenance Dose in Obese Patients with Moderate to Severe Plaque-Type Psoriasis. J Invest Dermatol 2011;131:S45.
Paul C, Solignac M. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions]. Ann Dermatol Venereol 2010;137:13–15.
Puig L. [Efficacy of treatment with infliximab in patients with moderate-severe psoriasis and high needs of therapy. A retrospective study of 43 patients]. Actas Dermosifiliogr 2008;99:30–35.
Reich K, Langley RG, Papp K, et al. Efficacy and safety of briakinumab vs. methotrexate in patients with moderate to severe psoriasis. Br J Dermatol 2011;165:4.
Reich K, Valdes J, Langley R, Yoo S. Efficacy and safety of ABT-874 versus methotrexate in patients with moderate to severe psoriasis. J Am Acad Dermatol 2011;64:AB147.
Reich K, Tsaneva M, Sundaram M, Bao Y. ABT-874 versus methotrexate in moderate to severe psoriasis: Effects on health-related quality-of-life outcomes. J Am Acad Dermatol 2011;64:AB156.
Riedl E, Torzicky M, Reider N, Moser-Oberthaler S. Infliximab in combination with low-dose methotrexate for the treatment of moderate to severe psoriasis. J Am Acad Dermatol 2009;60:AB170.
Searles G, Bissonnette R, Landells I, et al. Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study. J Cutan Med Surg 2009;13:S131–38.
Siu K, Strober B. A retrospective study to evaluate the safety, tolerability, and efficacy of the combination of cyclosporine and etanercept for the treatment of moderate to severe psoriasis. J Am Acad Dermatol 2006;543:AB199.
Smith EC, Riddle C, Menter MA, et al. Combining systemic retinoids with biologic agents for moderate to severe psoriasis. Int J Dermatol 2008;47:514–18.
Talamonti M, Teoli M, Botti E, Spallone G, Chimenti S, Costanzo A. Patients with moderate to severe plaque psoriasis: one year after the European Medicines Agency recommendation of efalizumab suspension. Dermatology 2011;222:250–55.
Yelverton C, Feldman S. Insurance coverage for biologics and phototherapy for severe psoriasis. J Am Acad Dermatol 2007;56 2:AB107.
Yildirim FE, Karaduman A, Pinar A, Aksoy Y. CD26/dipeptidyl-peptidase IV and adenosine deaminase serum levels in psoriatic patients treated with cyclosporine, etanercept, and psoralen plus ultraviolet A phototherapy. Int J Dermatol 2011;50: 948–55.
Zaragoza V, Perez A, Sanchez JL, et al. [Long-term safety and efficacy of etanercept in the treatment of psoriasis]. Actas Dermosifiliogr 2010;101:47–53.
Excluded because the study did not report our outcome of interest or determine the association between patient or disease charactersitics (n=8)
Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol 2011;165:1066–73.
Gattu S, Wu JJ, Koo JY. Sequential therapy with cyclosporine and adalimumab in patients with severe plaque psoriasis: a series of five cases. J Invest Dermatol 2009;129:275.
Papp K, Signorovitch J, Mulani P, Bao Y. Comparison of benefit-risk profiles for adalimumab, methotrexate, and placebo in the treatment of moderate to severe psoriasis. J Am Acad Dermatol 2010;62:AB126.
Prignano F, Ruffo G, Ricceri F, Pescitelli L, Lotti T. A global approach to psoriatic patients through PASI score and Skindex-29. G Ital Dermatol Venereol 2011;146:47.
Reich K, Signorovitch J, Ramakrishnan K, Gupta S, Mulani P. Risk-Benefit Analysis of Adalimumab Versus Methotrexate and Placebo for the Treatment of Moderate to Severe Psoriasis: Comparison of Adverse Event-Free Response Days in the CHAMPION Trial. J Invest Dermatol 2009;129:S26.
Reich K, Yu AP, Mulani P, Gupta S. Risk-benefit analysis of adalimumab versus methotrexate and placebo for the treatment of moderate to severe psoriasis: Comparison of adverse event-free remission days in the CHAMPION trial. J Am Acad Dermatol 2009;60:AB178.
Rivera R, Garcia-Doval I, Carretero G, et al. [BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report]. Actas Dermosifiliogr 2011;102:132–41.
Serrao R, Davis MD. Goeckerman treatment for remission of psoriasis refractory to biologic therapy. J Am Acad Dermatol 2009;60: 348–49.

From: Appendix C, Excluded Studies From Full-Text Review

Cover of Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis
Biologic and Nonbiologic Systemic Agents and Phototherapy for Treatment of Chronic Plaque Psoriasis [Internet].
Comparative Effectiveness Reviews, No. 85.
Lee S, Coleman CI, Limone B, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.